Patient with endometriotic cyst at least 3 cm in diameter Endometriosis
Conditions
Interventions
no treatment,Desogestrel (0.15 mg/d) (Cerazette®) prescribe 2 tab/d for 28-
35 days ,1 tablet of Marvelon® compose of Ethinyl estradiol (0.03 mg/tab) & Desogestrel (0.15 mg/tab)
prescribe 1 tab/d for 28-
35 days
Active Comparator No treatment,Active Comparator Drug,Active Comparator Drug
None,Desogestrel 150 mg,Ethinyl estradiol (0.03 mg/tab) & Desogestrel (0.15 mg/tab) (Marvelon®)
Sponsors
Faculty of Medicine, Ramathibodi hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1 healthy women age 18 40 yrs 2 diagnose as endometrioma with more than 3 cm in 3 No history of hormonal usage within 3 months or no treatment of depot medroxyprogesterone acetate DMPA or GnRH agonist past 9 months 4 no contraindication for Ethinyl estradiol and Desogestrel
Exclusion criteria
Exclusion criteria: 1) subjects with underlying disease which is not appropiate for taking combine pill, Ethinyl estradiol and Desgestrel 2) Contraindicate to Ethinyl estradiol ���Desgestrel 3) cannot tolerate to OC 4) deny to be recruited in the study 5) pathological report not endometriosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cell proliferation by Ki IHC, 1 month positive stained cells/100 cells,apoptosis by TUNEL assay 1 month positive stained cells/100 cells,antiapoptosis marker BCl2 1 month postive stained cells/100 cells | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunohistochemistry for macrophage (CD68) 1 month cell number of positive stained CD68 ,Immunohistochemistry for NK cells (CD57) 1 month cell number of positive stained CD57 | — |
Countries
thailand
Contacts
Public ContactSiriluk Tantanavipas
Mahidol University
Outcome results
None listed